【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications

2024年6月24日 14:03 • Request for Product • 阅读 182

If your company is interested in this opportunity, please contact us as soon as possible!

【Project Code】BP-20240516-L-EE-108

【Demand Party】MNCs, major Chinese pharmaceutical companies, US biotech companies

【Disease Area】Metabolism

【Indications】Obesity, Overweight

【Target/MOA】ActRIIB Inhibitor

【Product Stage】PCC, Preclinical, Phase 1 Clinical

【Molecular Entity】All are considered

【Rights】Overseas rights (outside of China or the Greater China Region), Global rights

【Cooperation Mode】Licensing

If your company is interested in this opportunity, please contact us as soon as possible!

Please indicate the project code (BP-20240516-L-EE-108).

We will discuss in detail with you. Thank you!

Contact person: Richard

Phone: 17821449819

WeChat: DrugTimes_BD

发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权

打赏

为好文打赏支持药时代共创新未来！

上一篇 2024年6月24日 13:50

下一篇 2024年6月24日 16:40

公众号

返回顶部